News | January 26, 2022
Cipla’s Q3FY22 PAT at Rs 729 cr.
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
Astec LifeSciences has reported its financial performance for the quarter ended December 31, 2021
Torrent Pharmaceuticals has reported consolidated financial results for the period ended December 31, 2021.
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
Go-ahead for pivotal clinical trial which is expected to commence by March
Biocon has reported consolidated financial results for the period ended December 31, 2021
Narayanan to lead SeQuent through next phase of consolidation and growth
Danny Bar-Zohar will become Global Head of R&D and Joern-Peter Halle will become Chief Strategy Officer
Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection. It will receive an upfront cash payment of US $ 100 million with the potential of US $ 5.2 billion in total milestones plus tiered royalties
The transaction is expected to close in the first quarter of 2022
Subscribe To Our Newsletter & Stay Updated
